Circulating insulin-like growth factor-binding protein 3 as prognostic biomarker in liver cirrhosis

Figure 2 Cumulative 90-d transplant-free survival of hospitalized patients with cirrhosis according to insulin-like growth factor-binding protein 3, acute-on-chronic liver failure, Child-Pugh and model for end-stage liver disease. The 90-d survival was 89.5% in patients without ACLF and with IGFBP-3 ≥ 0.86 mcg/mL, 70.7% for those with IGFBP-3 < 0.86 mcg/mL only, 42.9% for those with ACLF only and 20.8% for patients with both ACLF and IGFBP-3 < 0.86 mcg/mL (A: P < 0.001). Similarly, survival probability was 90.8% in patients Child-Pugh A/B and with IGFBP-3 ≥ 0.86 mcg/mL, 78.9% for those with IGFBP-3 < 0.86 mcg/mL only, 54.8% for those Child-Pugh C only and 36.4% for Child-Pugh C patients with IGFBP-3 < 0.86 mcg/mL (B: P < 0.001). The 90-d Kaplan-Meier survival probability was 90.7% in patients with MELD < 17 and IGFBP-3 ≥ 0.86 mcg/mL, 80.5% for those with MELD < 17 and IGFBP-3 < 0.86 mcg/mL, 56.3% for those with MELD ≥ 17 and IGFBP-3 ≥ 0.86 mcg/mL and 31.7% for patients with both MELD ≥ 17 and IGFBP-3 < 0.86 mcg/mL (C: P < 0.001). ACLF: Acute-on-chronic liver failure; IGFBP-3: Insulin-like growth factor-binding protein 3; MELD: Model for end-stage liver disease.